ArticleJournal of clinical tuberculosis and other mycobacterial diseases2025
The synergy of therapeutic vaccination and timely diagnosis for TB control in high-burden settings: Nunavut as a case study.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although the overall prevalence of Tuberculosis (TB) in Canada is relatively low, Indigenous communities are disproportionately burdened, with active TB rates exceeding those of Canadian-born non-Indigenous populations by more than 55-fold. In response, the Government of Canada and Inuit Tapiriit Kanatami have launched an initiative to eliminate TB among Inuit by 2030. We evaluated strategies underpinning this initiative, including the potential use of therapeutic TB vaccines that are currently undergoing clinical trials. Methods: We developed an agent-based model of TB transmission dynamics that includes the demographic distributions and household structure of the Nunavut population, as well as TB progression at the individual level. We simulated the model with combinations of interventions, including treatment of active cases, testing, and contact-tracing. We further evaluated the impact of vaccinating active TB cases and those identified with latent TB infection (LTBI) to project the reduction of TB incidence over a 20-year time horizon starting from 2025. In scenario analyses, we considered different vaccine efficacies, diagnostic delays, and rates of contact-tracing. Results: In the absence of a therapeutic vaccine, we estimated a maximum reduction of 20.0% (95% Uncertainty Range [UR]: 15.5% - 24.8%) in active TB incidence with a 4-week diagnostic delay and 75% contact-tracing rate, over the simulated time horizon. Vaccination of active TB cases and those identified with LTBI was projected to decrease the incidence by 87.0% (95% UR: 68.8% - 97.5%) by 2045. Contact-tracing of non-household members exhibited a marginal effect on reducing TB incidence in the presence of vaccination, especially when diagnostic delay was shortened. Conclusions: Our findings highlight the importance of rapid TB diagnosis. The availability of therapeutic vaccines can substantially enhance TB control efforts towards achieving the elimination goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.